Genmab drops zalutumumab

Genmab has shelved zalutumumab, a drug for squamous cell carcinoma of the head and neck, to focus on other drugs in its pipeline. The developer announced last year that it would hunt for a partner to finance costly trials of the drug, which were necessary to achieve U.S. approval. But Genmab wasn't able to find any developers to foot the bill. Article